CD38 and autoimmune thrombocytopenic purpura: Recently, many new molecular targeted agents such as spleen tyrosine kinase inhibitors and neonatal Fc receptor inhibitors have been developed as new treatment options for ITP, and furthermore other agents of new mechanism of action such as Bruton’s tyrosine kinase inhibitors and CD38 monoclonal antibody are under development.